Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Bristol Myers Squibb Co.

Related BMY
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Pamela Anderson And Hepatitis C: Which Drug Makers Are Working On A Cure?
Clinton's Price Caps Are A Non-Starter: Liana Moussatos Of Wedbush Securities (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Bristol Myers Squibb Co. (NYSE: BMY), and slightly raised its price target from $38.00 to $39.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Bristol Myers Squibb Co. closed on Tuesday at $34.22.

Latest Ratings for BMY

Sep 2015UBSUpgradesNeutralBuy
Aug 2015JefferiesMaintainsHold
Aug 2015Piper JaffrayUpgradesUnderN

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (BMY)

View Comments and Join the Discussion!

Get Benzinga's Newsletters